High-dose methylprednisolone pulse therapy during refractory COVID-19 acute respiratory distress syndrome: a retrospective observational study

Table 1 Patient Characteristics, ICU Treatment and Outcome

		Methylprednisolone Pulse Therapy
Age [years]		55 ± 12.2
Sex m/f n [%]		25/12 [68/32]
BMI [kg/m²]		29 ± 5.1
Comorbidities n [%]
	Arterial Hypertension	13 [35]
	Coronary Artery Disease	4 [11]
	Diabetes mellitus	8 [22]
	Chronic obstructive pulmonary disease	1 [3]
	Chronic Renal Failure	0 [0]
SAPS II Admission		40 ± 18.1
SAPS II Maximum		54 ± 19
Mechanical Ventilation [days]		40 ± 31
vvECMO Therapy n [%]		21 [57]
Duration vvECMO [days]		40 ± 29.5
Duration ICU Treatment [days]		42 ± 34
Survival n [%]		24 [65]

BMI: Body Mass Index; SAPS II: Simplified Acute Physiology Score II; vvECMO: Venovenous Extracorporeal Membrane Oxygenation; ICU: Intensive Care Unit

ISSN: 1471-2466